Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)

Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET) is a phase 1/2, interventional study registered as NCT04235114 by University of Saskatchewan, with a registry enrolment figure of 14 participants, started 2020-02-01 and due to reach its primary completion in 2026-09. Interventions recorded: 50 mg 89Zr-DFO-Nimotuzumab; 1 mg 89Zr-DFO-Nimotuzumab. Conditions listed: Lung Cancer; Colorectal Cancer. Primary outcome: The observation of differences in 89Zr-DFO-nimotuzumab uptake between the tumors and normal tissues using PET/CT.. Colorectal eligibility wording from the registry: "* Not currently pregnant or nursing: If female subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), post-menopausal (cessation of menses for \> 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test is negative". Sites: Canada. No results are recorded here; the registry entry is the source.